<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004324</url>
  </required_header>
  <id_info>
    <org_study_id>K0106</org_study_id>
    <nct_id>NCT05004324</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD)</brief_title>
  <acronym>smart(FURIN)</acronym>
  <official_title>A Two-stage, Multi-center, Randomized, Double-Blind, Placebo Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kang Stem Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kang Stem Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial study is two-stage, multi-center, randomized, double-blind, placebo&#xD;
      controlled, phase 3 clinical trial to evaluate the efficacy and safety of FURESTEM-AD Inj.&#xD;
      for moderate to severe chronic atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EASI(Eczema Area and Severity Index)-50</measure>
    <time_frame>12 weeks</time_frame>
    <description>Ratio of subject whose Eczema Area and Severity Index (EASI) decreased over 50% as contrasted with baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EASI(Eczema Area and Severity Index)-75</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Ratio of subjects whose Eczema Area and Severity Index (EASI) decreased over 75% as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI(Eczema Area and Severity Index)-50</measure>
    <time_frame>2,4,8 weeks</time_frame>
    <description>Ratio of subjects whose Eczema Area and Severity Index (EASI) decreased over 50% as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI(Eczema Area and Severity Index) index</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Change and rate of change in Eczema Area and Severity Index (EASI) index as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA(Investigator's Global Assessment) Score</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Proportion of subjects who Investigator's Global Assessment (IGA) score 0 or 1 and at least 2 points reduction in IGA score as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORAD(SCORing Atopic Dermatitis)-50</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Ratio of subjects whose SCORing Atopic Dermatitis (SCORAD) decreased over 50% as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORAD(SCORing Atopic Dermatitis) index</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Change and rate of change in SCORing Atopic Dermatitis (SCORAD) index as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSA(Body Surface Area)</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Change and rate of change in Body Surface Area (BSA) as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst daily Pruritus NRS(Numerical Rating Scale)</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Rate of change in Worst daily Pruritus Numerical Rating Scale (NRS) as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily Pruritus NRS(Numerical Rating Scale)</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Rate of change in Average daily Pruritus Numerical Rating Scale (NRS) as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst daily Pruritus NRS(Numerical Rating Scale) - 4 points</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Proportion of patients at least 4 points reduction in Worst daily Pruritus Numerical Rating Scale (NRS) as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POEM(Patient-Oriented Eczema Measure)</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Change and rate of change in Patient-Oriented Eczema Measure (POEM) as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI(Dermatology Life Quality Index)</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Change and rate of change in Dermatology Life Quality Index (DLQI) as contrasted with baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medicine</measure>
    <time_frame>up to 12, 24 weeks</time_frame>
    <description>Total number of use and consumed amount of rescue medicine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Furestem-AD Inj.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product name: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL&#xD;
baseline (0week) Experimental group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).&#xD;
After 12 weeks, Experimental group will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo&#xD;
baseline (0week) Placebo comparator group will receive placebo.&#xD;
After 12 weeks, Placebo comparator group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL</intervention_name>
    <description>the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)</description>
    <arm_group_label>Furestem-AD Inj.</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)</description>
    <arm_group_label>Furestem-AD Inj.</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 19 years and older at time of informed consent&#xD;
&#xD;
          2. Subjects diagnosed with atopic dermatitis based on the Hanifin and Rajka diagnostic&#xD;
             criteria&#xD;
&#xD;
          3. Subjects with chronic atopic dermatitis that has been present for at least 1 year&#xD;
             before screening&#xD;
&#xD;
          4. Subjects with moderate to severe atopic dermatitis as indicated by:&#xD;
&#xD;
               -  EASI score ≥ 16 points at the time of screening and baseline (Day 1),&#xD;
&#xD;
               -  IGA score ≥ 3 points at the time of screening and baseline (Day 1), and&#xD;
&#xD;
               -  BSA affected by atopic dermatitis ≥ 10% at the time of screening and baseline&#xD;
                  (Day 1)&#xD;
&#xD;
          5. Subjects who have documented history of insufficient response to stable use of atopic&#xD;
             dermatitis treatment within 24 weeks before screening, or inability to receive such&#xD;
             treatment because of safety issues&#xD;
&#xD;
          6. Subjects who are willing to apply a stable dose of non-medicated topical moisturizer&#xD;
             at least twice daily for at least 7 days before the baseline (Day 1) visit and the&#xD;
             duration of the study&#xD;
&#xD;
          7. Women of childbearing potential who use appropriate contraceptive methods during this&#xD;
             trial period&#xD;
&#xD;
          8. Subjects who have voluntarily agreed to participate in this trial in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with the following history of disease or surgery/procedure at screening&#xD;
&#xD;
               1. Malignancy or lympho-proliferative disease within 5 years before screening&#xD;
                  (except completely treated carcinoma in situ of the cervix, or completely treated&#xD;
                  and resolved non-metastatic squamous or basal cell carcinoma of the skin)&#xD;
&#xD;
               2. organ transplants&#xD;
&#xD;
               3. History of mental illness, drug or alcohol abuse within 2 years before screening,&#xD;
                  as per Investigator's opinion&#xD;
&#xD;
          2. Subjects with the following underlying disease at screening&#xD;
&#xD;
               1. Chronic active, acute infection or superficial skin infections requiring&#xD;
                  treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals&#xD;
                  or antifungals;&#xD;
&#xD;
               2. Skin diseases, pigmentation, or extensive scarring other than atopic dermatitis&#xD;
                  that may affect the efficacy evaluations of the study&#xD;
&#xD;
          3. Renal dysfunction with serum creatinine level &gt; 2.0 mg/dL at screening&#xD;
&#xD;
          4. Liver dysfunction with alanine aminotransferase (ALT) or aspartate aminotransferase&#xD;
             (AST) levels exceeding 2.5 times the upper limit of the normal range (ULN) at the time&#xD;
             of screening&#xD;
&#xD;
          5. Subjects with the history of using leukotriene receptor antagonists, systemic&#xD;
             steroids, phototherapy, systemic immunosuppressants/modulators including janus kinase&#xD;
             (JAK) inhibitors, and/or any other systemic therapy (not mentioned in Exclusion&#xD;
             Criteria 6 and 8) to treat atopic dermatitis or symptoms of atopic dermatitis&#xD;
             (approved or off-label use) within 4 weeks before baseline (Day 1)&#xD;
&#xD;
          6. Subjects with the history of using systemic or topical antihistamines, topical&#xD;
             corticosteroids (TCS), topical calcineurin inhibitors (TCIs), or topical&#xD;
             phosphodiesterase 4 (PDE4) inhibitors within 2 weeks before baseline (Day 1)&#xD;
&#xD;
          7. Allergen immunotherapy within 6 months before baseline (Day 1)&#xD;
&#xD;
          8. Subjects with the history of receipt of the following treatments before baseline (Day&#xD;
             1)&#xD;
&#xD;
               1. B cell-depleting agents including rituximab within 6 months&#xD;
&#xD;
               2. Other biologics including dupilumab within 5 half-lives (if known) or 12 weeks,&#xD;
                  whichever is longer&#xD;
&#xD;
          9. Subjects with regular use (more than two times per a week) of a tanning booth/parlor&#xD;
             within 4 weeks before screening visit&#xD;
&#xD;
         10. Subjects with the history of a live (attenuated) vaccine injection within 12 weeks&#xD;
             before baseline (Day 1) or the plan to inject a live (attenuated) vaccine within 24&#xD;
             weeks after randomization&#xD;
&#xD;
         11. Subjects who are deemed to require prohibited concomitant medications drug/therapy&#xD;
             during the study period&#xD;
&#xD;
         12. Subjects with uncontrolled chronic disease that might require administration of oral&#xD;
             corticosteroids such as uncontrolled and severe asthma&#xD;
&#xD;
         13. Pregnant/lactating women and men and women of childbearing potential who plan to&#xD;
             become pregnant or who refuse to use appropriate contraceptive methods during the&#xD;
             study period&#xD;
&#xD;
         14. Subjects with the history of receipt of any investigational products or devices from&#xD;
             another clinical trial within 4 weeks or 5 half-lives (if known) pior to screening&#xD;
&#xD;
         15. Positive serology for hepatitis B or C, or for HIV&#xD;
&#xD;
         16. Subjects with prior use of FURESTEM-AD&#xD;
&#xD;
         17. Subjects with history of anaphylaxis&#xD;
&#xD;
         18. Subjects who are deemed to have difficulty in performing this study by the judgment of&#xD;
             the Investigator and those with other medical findings that are unsuitable for&#xD;
             participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeonglib Park, professor (CI)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucheon Hospital, Soonchunhyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yangwon Lee, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanguk Son, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bakrin Yoo, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangdong Kyunghee University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jihyun Lee, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donghoon Lee, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chanho Na, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chosun University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yooin Bae, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Dongtan Seongsim Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyunchang Ko, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yangsan Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Younghyun Jang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeongeun Kim, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea Eunpyeong St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minkyung Shin, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanghyun Cho, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Incheon St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheonuk Park, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Gangnam Seongsim Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jooyeon Ko, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taeyoung Han, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nowon Eulji University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiyoung Ahn, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noori Kim</last_name>
    <phone>2-888-1590</phone>
    <phone_ext>82</phone_ext>
    <email>nrkim@kangstem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seulbi Lee</last_name>
    <phone>2-888-1590</phone>
    <phone_ext>82</phone_ext>
    <email>sblee@kangstem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Jeollanam-do</state>
        <zip>61453</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chanho Na, professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>AD</keyword>
  <keyword>Stem cell</keyword>
  <keyword>Furestem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

